At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
pro-ANPother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of Atrial Natriuretic Peptide in Assessing of Fluid Status in Cardiac Surgery Patients
In Brief
A clinical study evaluating pro-ANP for Fluid Overload and 5 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Biomarkers can play a significant role in fluid status assessment intraoperatively.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFluid Overload, Fluid Loss, Volume Overload, Cardiac Disease, Cardiac Output, Low, Cardiac Output, High
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartSep 2021
First PostedOct 2021
Primary CompletionMar 2022
Study CompletionApr 2022
TodayJul 2026
First PostedOct 7, 2021
Enrollment StartSep 23, 2021
Primary CompletionMar 28, 2022
Study CompletionApr 7, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.7 years ago
Interventions
pro-ANPother
pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.